Skip to main content
Top
Published in: Journal of General Internal Medicine 9/2009

01-09-2009 | Populations at Risk

Race/Ethnicity and Risk of AIDS and Death Among HIV-infected Patients with Access to Care

Authors: Michael J. Silverberg, PhD, MPH, Wendy Leyden, MPH, Charles P. Quesenberry Jr., PhD, Michael A. Horberg, MD, MAS

Published in: Journal of General Internal Medicine | Issue 9/2009

Login to get access

ABSTRACT

BACKGROUND

Prior studies evaluating racial/ethnic differences in responses to antiretroviral therapy (ART) among HIV-infected patients have not adequately accounted for many potential confounders, and few have included Hispanic patients.

OBJECTIVE

To identify racial/ethnic differences in ART adherence, and risk of AIDS and death after ART initiation for HIV patients with similar access to care.

DESIGN

Retrospective cohort study.

PARTICIPANTS

4,686 HIV-infected patients (66% White, 20% Black, and 14% Hispanic) initiating ART and who were enrolled in an integrated healthcare system.

MEASUREMENTS

Main outcomes evaluated were ART adherence, new AIDS clinical events, and all-cause mortality. The potential confounding effects of demographics, socioeconomic status, ART parameters, HIV disease stage, and other clinical parameters were considered in multivariable models.

RESULTS

Adjusted mean adherence levels were higher among White (70.1%; ref) compared with Black (64.2%; P < 0.001) and Hispanic patients (65.2%; P < 0.001). Adjusted hazard ratios (HR) for the risk of new AIDS events (White patients as reference) were 1.3 (P = 0.09) for Black and 0.9 (P = 0.64) for Hispanic patients. The adjusted HR for AIDS comparing Hispanic to Black patients was 0.7 (P = 0.11). Hispanic patients had fewer deaths compared with other racial/ethnic groups, particularly cancer and cardiovascular-related. However, adjusted HRs for death were 1.2 (P = 0.37) and 0.9 (P = 0.62) for Black and Hispanic patients, respectively, compared with White patients and 0.9 (P = 0.63) for Hispanic compared with Black patients. Adjustment for adherence did not change inferences for AIDS or death.

CONCLUSIONS

In the setting of similar access to care, we did not observe a disparity for the risk of clinical events for racial/ethnic minorities, despite lower ART adherence.
Literature
1.
go back to reference CDC. Racial/ethnic disparities in diagnoses of HIV/AIDS–33 states, 2001–2005. MMWR Morb Mortal Wkly Rep. 2007;56:189–93. CDC. Racial/ethnic disparities in diagnoses of HIV/AIDS–33 states, 2001–2005. MMWR Morb Mortal Wkly Rep. 2007;56:189–93.
2.
go back to reference CDC. HIV/AIDS Surveillance Report, 2005. 2007;17:1–54. CDC. HIV/AIDS Surveillance Report, 2005. 2007;17:1–54.
3.
go back to reference Heron MP, Smith BL. Deaths: leading causes for 2003. Hyattsville, MD: National vital statistics reports; 2007;15:1–92. Heron MP, Smith BL. Deaths: leading causes for 2003. Hyattsville, MD: National vital statistics reports; 2007;15:1–92.
4.
go back to reference Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39:537–44.PubMed Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39:537–44.PubMed
5.
go back to reference Giordano TP, Morgan RO, Kramer JR, et al. Is there a race-based disparity in the survival of veterans with HIV? J Gen Intern Med. 2006;21:613–7.PubMedCrossRef Giordano TP, Morgan RO, Kramer JR, et al. Is there a race-based disparity in the survival of veterans with HIV? J Gen Intern Med. 2006;21:613–7.PubMedCrossRef
6.
go back to reference Jensen-Fangel S, Pedersen L, Pedersen C, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002;35:1541–48.PubMedCrossRef Jensen-Fangel S, Pedersen L, Pedersen C, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002;35:1541–48.PubMedCrossRef
7.
go back to reference Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15:1115–23.PubMedCrossRef Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15:1115–23.PubMedCrossRef
8.
go back to reference Silverberg MJ, Wegner SA, Milazzo MJ, et al. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006;20:1531–8.PubMedCrossRef Silverberg MJ, Wegner SA, Milazzo MJ, et al. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006;20:1531–8.PubMedCrossRef
9.
go back to reference Smith PR, Sarner L, Murphy M, et al. Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals. J Clin Virol. 2003;26:101–7.PubMedCrossRef Smith PR, Sarner L, Murphy M, et al. Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals. J Clin Virol. 2003;26:101–7.PubMedCrossRef
10.
go back to reference Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;47:441–8.PubMedCrossRef Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;47:441–8.PubMedCrossRef
11.
go back to reference McGinnis KA, Fine MJ, Sharma RK, et al. Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health. 2003;93:1728–33.PubMedCrossRef McGinnis KA, Fine MJ, Sharma RK, et al. Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health. 2003;93:1728–33.PubMedCrossRef
12.
go back to reference Merriman NA, Porter SB, Brensinger CM, Reddy KR, Chang KM. Racial difference in mortality among U.S. veterans with HCV/HIV coinfection. Am J Gastroenterol. 2006;101:760–7.PubMedCrossRef Merriman NA, Porter SB, Brensinger CM, Reddy KR, Chang KM. Racial difference in mortality among U.S. veterans with HCV/HIV coinfection. Am J Gastroenterol. 2006;101:760–7.PubMedCrossRef
13.
go back to reference Messeri P, Lee G, Abramson DM, Aidala A, Chiasson MA, Jessop DJ. Antiretroviral therapy and declining AIDS mortality in New York City. Med Care. 2003;41:512–21.PubMedCrossRef Messeri P, Lee G, Abramson DM, Aidala A, Chiasson MA, Jessop DJ. Antiretroviral therapy and declining AIDS mortality in New York City. Med Care. 2003;41:512–21.PubMedCrossRef
16.
go back to reference Horberg MA, Hurley LB, Silverberg MJ, Kinsman CJ, Quesenberry CP. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44:531–9.PubMedCrossRef Horberg MA, Hurley LB, Silverberg MJ, Kinsman CJ, Quesenberry CP. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44:531–9.PubMedCrossRef
17.
go back to reference Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167:684–91.PubMedCrossRef Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167:684–91.PubMedCrossRef
18.
go back to reference Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.PubMedCrossRef Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.PubMedCrossRef
19.
go back to reference Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:1–19. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:1–19.
20.
go back to reference Bendel RB, Afifi AA. Comparison of stopping rules in forward "stepwise" regression. J Am Stat Assoc. 1977;72:46–53.CrossRef Bendel RB, Afifi AA. Comparison of stopping rules in forward "stepwise" regression. J Am Stat Assoc. 1977;72:46–53.CrossRef
21.
go back to reference Hosmer DW, Lemeshow S. Applied logistic regression, second edition. Hoboken, NJ: John Wiley & Sons, Inc.; 2000.CrossRef Hosmer DW, Lemeshow S. Applied logistic regression, second edition. Hoboken, NJ: John Wiley & Sons, Inc.; 2000.CrossRef
22.
go back to reference Cox DR, Oates D. Analysis of survival data. London and New York: Chapman and Hall; 1984. Cox DR, Oates D. Analysis of survival data. London and New York: Chapman and Hall; 1984.
23.
go back to reference Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York, NY: Oxford University Press; 1995. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York, NY: Oxford University Press; 1995.
24.
go back to reference Epidemiology of HIV/AIDS–United States, 1981–2005. MMWR Morb Mortal Wkly Rep. Jun 2 2006;55:589–92. Epidemiology of HIV/AIDS–United States, 1981–2005. MMWR Morb Mortal Wkly Rep. Jun 2 2006;55:589–92.
25.
go back to reference Hayes-Bautista DE, Baezconde-Garbanati L, Schink WO, Hayes-Bautista M. Latino health in California, 1985–1990: implications for family practice. Fam Med. 1994;26:556–62.PubMed Hayes-Bautista DE, Baezconde-Garbanati L, Schink WO, Hayes-Bautista M. Latino health in California, 1985–1990: implications for family practice. Fam Med. 1994;26:556–62.PubMed
26.
go back to reference Markides KS, Coreil J. The health of Hispanics in the southwestern United States: an epidemiologic paradox. Public Health Rep. 1986;101:253–65.PubMed Markides KS, Coreil J. The health of Hispanics in the southwestern United States: an epidemiologic paradox. Public Health Rep. 1986;101:253–65.PubMed
27.
go back to reference Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703–10.PubMedCrossRef Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703–10.PubMedCrossRef
28.
go back to reference Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82–92.PubMed Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82–92.PubMed
29.
go back to reference Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS. 2004;18:683–88.PubMedCrossRef Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS. 2004;18:683–88.PubMedCrossRef
30.
go back to reference Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38:320–28.PubMed Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38:320–28.PubMed
31.
go back to reference Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756–65.PubMedCrossRef Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756–65.PubMedCrossRef
32.
go back to reference Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386–95.PubMed Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386–95.PubMed
33.
go back to reference Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190:1860–8.PubMedCrossRef Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190:1860–8.PubMedCrossRef
34.
go back to reference Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr. 2007;44:411–6.PubMedCrossRef Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr. 2007;44:411–6.PubMedCrossRef
35.
go back to reference Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007;46:547–54.PubMedCrossRef Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007;46:547–54.PubMedCrossRef
36.
go back to reference Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7:85–98.PubMedCrossRef Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7:85–98.PubMedCrossRef
37.
go back to reference Giordano TP, Wright JA, Hasan MQ, White AC Jr., Graviss EA, Visnegarwala F. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis. 2003;37:433–37.PubMedCrossRef Giordano TP, Wright JA, Hasan MQ, White AC Jr., Graviss EA, Visnegarwala F. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis. 2003;37:433–37.PubMedCrossRef
38.
go back to reference Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–7.PubMed Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–7.PubMed
Metadata
Title
Race/Ethnicity and Risk of AIDS and Death Among HIV-infected Patients with Access to Care
Authors
Michael J. Silverberg, PhD, MPH
Wendy Leyden, MPH
Charles P. Quesenberry Jr., PhD
Michael A. Horberg, MD, MAS
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 9/2009
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-009-1049-y

Other articles of this Issue 9/2009

Journal of General Internal Medicine 9/2009 Go to the issue

Reflections

REFLECTIONS

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine